Boston Scientific Corporation · NYSE:BSX
Boston Scientific — SPAC Merger (January 2006)
33 slides from Boston Scientific's SPAC merger presentation, Jan 9, 2006
Slide 1: Creating a Global Leader in Cardiovascular Devices
Link to searchable text of slide shown above
Slide 2: Safe Harbor: Forward-Looking Statements
Link to searchable text of slide shown above
Slide 3: Link
Link to searchable text of slide shown above
Slide 4: Link
Link to searchable text of slide shown above
Slide 5: Link
Link to searchable text of slide shown above
Slide 6: Link
Link to searchable text of slide shown above
Slide 7: Link
Link to searchable text of slide shown above
Slide 8: Link
Link to searchable text of slide shown above
Slide 9: Link
Link to searchable text of slide shown above
Slide 10: Vascular Businesses Divestiture: The Abbott Agreement
Vascular Businesses Divestiture Coen The Abbott A ment = Binding definitive agreement " Total consideration to BSC of $4.3 billion = $3.8 billion up-front payment = $250 million upon U.S. FDA approval = $250 million upon Japanese regulatory approval = BSC to receive a five-year $700 million subordin
Slide 11: The Abbott Agreement: DES Sharing
The Abbott Agreement _ Ee ate DES Sharin — = BSC to share rights to Guidant’s DES portfolio = Rights to intellectual property = Rights to technology transfers = Sharing of regulatory and clinical trial assets = Rights to iterate, manufacture and commercialize technology = Worldwide interim supply ag
Slide 12: Delivering what's next
Soreitific Delivering what's next.”
Slide 13: Accelerating Revenue Growth
Accelerating Revenue Growth Sheenhc Proforma Co les == (Oolars in Bitlons) $10.0 2007 2008 2009 2010 2011
Slide 14: Accelerating Proforma Adjusted EPS
Boston, Accelerating Proforma Adjusted ERS” Scientific 2007 2008 2009 2010 2011 Ie: Son Sint ot Cpt Gn’ bn: tna Ad ES pnd tn ay 3G pa nha
Slide 15: Strong Proforma Operating Cash Flow
Slide 16: Strong Cash Flow Generation
Boston, Strong Cash Flow Generation Scientific {Oolars in Bitfons) 3/31/2006 2006 2007 2008 2009 2010 Gross Debt 10.4 10.7 8.9 6.9 54 5.4 Cash 0.4 1.3 1.3 15 2.2 48
Slide 17: Strong Credit Profile
Strong Credit Profile Gross Debt / EBITDA Net Debt / EBITDA Gross Debt / Capitalization Net Debt / Capitalization FFO/ Gross Debt Bsc LTM 9/30/05, 1.6x 1.0x 39% 25% Pro Forma LTM 3/31/06 3.8x 3.5x 41% 36% Boston, Scientific Pro Forma LTM 12/31/08. 1.6x 1.3x 27% 21% 56%
Slide 18: Delivering what's next
Secanne Delivering what's next.”
Slide 19: Shareholder Value Creation
Shareholder Value Creation Ser ie Ss " Diversification and growth profile should deliver P/E multiple expansion = Our goal is to exceed Wall Street current earnings consensus
Slide 20: Roadmap to Completing the Transaction
Roadmap to Completing the Transaction te ¥ Completed confirmatory due diligence y Discussions with antitrust agencies Y Discussions with rating agencies Y Definitive divestiture agreement with Abbott ¥ Definitive merger agreement delivered to Guidant = Boston Scientific and Guidant enter into a defi
Slide 21: Link
Link to searchable text of slide shown abov e
Slide 22: Key Value Drivers
Key Value Drivers Seana = Achieving enhanced growth and diversification = Acquiring a leading CRM position = Adding a second drug-eluting stent program = Transforming operating capabilities
Slide 23: Preeminent pure play in medical devices
Endosurgery 16% Preeminent pure play in medical devices
Slide 24: Key Value Drivers: Acquiring Leading Business in High-Growth Center
Key Value Drivers Boston. : Acquiring Leading Business:in-High-Growth Cente | sigs CAGR CRT-Ds 23% Pacemakers 3% = Pacemakers CRT-Ds _IeDs
Slide 25: Key Value Drivers: CRM Market Recovery
Key Value Drivers Senate CRM Market SCOVETY GOS : =a Conservative view 0% + T T T T T T 1 2004 2005 2006 2007 2008 2009 2010 2011 sare copay tne 2
Slide 26: CRM Recovery Drivers
CRM Recovery Drivers __ Ee ate " Quality and = CRM pipeline = Market perception
Slide 27: International penetration
International penetration Expanding indications Growing complexity
Slide 28: Growth Through DES Platform Diversification
Key Value Drivers Boston, Growth Through DES Platform»Diversification. Scientific = TAXUS position = Immediate access = Pipeline « Differentiated platforms = Primary program = ‘Olimus alternative TECHNOLOGY PORTFOLIO 2
Slide 29: Creating a Global Leader in Cardiovascular Devices
Slide 30: Transforming Operating Capabilities
Transforming Operating Capabilities Boston ic International — Operations = Efficiencies = Therapies
Slide 31: Creating The World's Cardiovascular Leader
Boston, Creating The World’ 's seis Scientific Cardiovascul Boston Scientific and Guidant Combination = Merges two innovative leaders with proven track records = Leverages strong financial capability to diversify into high growth CRM opportunity and complementary DES technology = Strategic and finan
Slide 32: Excited About Moving Forward...
Excited About Moving Forward... Coen = We look forward to the Guidant Board embracing our proposal this week. = We believe we can close this transaction by the end of Q1. = We believe this combination will be an historic one benefiting shareholders, employees, customers and their patients. = We are
Slide 33: Searchable text section of graphics shown above
Searchable text section of graphics shown above Fil ed by Boston Scientific Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Guidant Corporation Commission File No.: 001-13388 [LOGO]